Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (23)

2023

  1. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  2. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

2022

  1. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

2021

  1. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

    Clinical Infectious Diseases, Vol. 73, Núm. 11, pp. 2009-2022

  2. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

    BMC Infectious Diseases, Vol. 21, Núm. 1

2019

  1. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  2. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505

  3. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379

2018

  1. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

    The Lancet HIV, Vol. 5, Núm. 4, pp. e162-e171

2017

  1. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

    PLoS ONE, Vol. 12, Núm. 4

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

    HIV Medicine, Vol. 17, Núm. 5, pp. 340-349

2015

  1. Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

  3. Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47

2014

  1. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  2. Peak bone mass in young HIV-infected patients compared with healthy controls

    Journal of Acquired Immune Deficiency Syndromes, Vol. 65, Núm. 2, pp. 207-212